Lantern Pharma Inc. Harnesses AI to Revolutionize Oncology Drug Development

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biotechnology company, is making strides in oncology drug development through its innovative use of artificial intelligence (AI) and machine learning. The company's proprietary RADR(R) platform, which integrates over 200 billion oncology-specific data points, is at the heart of its mission to redefine cancer treatment. With three lead drug candidates currently in clinical development, Lantern Pharma is targeting some of the most challenging oncology markets, including non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), and non-Hodgkin’s lymphoma (NHL).

The significance of Lantern Pharma's work lies in its ability to significantly reduce the time and cost associated with bringing new cancer therapies to market. The company's AI-driven approach has enabled it to advance drug programs from initial insights to first-in-human clinical trials in just 2-3 years, at approximately $2.5 million per program. This efficiency is unparalleled in the biotech industry and represents a potential paradigm shift in how cancer treatments are developed.

Furthermore, Lantern Pharma's Starlight Therapeutics initiative extends its impact into brain and central nervous system (CNS) cancers, including pediatric indications. The company's portfolio has been bolstered by multiple FDA designations, such as Fast Track, Orphan Drug, and Rare Pediatric Disease status, which facilitate faster regulatory pathways for its therapies. These advancements underscore the importance of Lantern Pharma's work in addressing unmet medical needs in oncology.

For more information on Lantern Pharma's groundbreaking work, visit https://ibn.fm/s1B45.